atenolol has been researched along with Atheroma in 1 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that nebivolol, a β-blocker with nitric oxide-mediated activity, compared with atenolol, a β-blocker without such activity, would decrease oxidative stress and improve the effects of endothelial dysfunction and wall shear stress (WSS), thereby reducing atherosclerosis progression and vulnerability in patients with nonobstructive coronary artery disease." | 5.22 | Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary ( Ahn, SG; Corban, MT; Dhawan, S; Eshtehardi, P; Giddens, DP; Gogas, BD; Hung, OY; Maynard, C; McDaniel, MC; Molony, D; Piccinelli, M; Quyyumi, AA; Rasoul-Arzrumly, E; Samady, H; Timmins, LH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hung, OY | 1 |
| Molony, D | 1 |
| Corban, MT | 1 |
| Rasoul-Arzrumly, E | 1 |
| Maynard, C | 1 |
| Eshtehardi, P | 1 |
| Dhawan, S | 1 |
| Timmins, LH | 1 |
| Piccinelli, M | 1 |
| Ahn, SG | 1 |
| Gogas, BD | 1 |
| McDaniel, MC | 1 |
| Quyyumi, AA | 1 |
| Giddens, DP | 1 |
| Samady, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease[NCT01230892] | Phase 4 | 29 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Presence of thin-cap fibroatheroma as defined by virtual histology-intravascular ultrasound (VH-IVUS) (NCT01230892)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 4 |
| Atenolol | 6 |
1 trial available for atenolol and Atheroma
| Article | Year |
|---|---|
Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Biomarkers; Coron | 2016 |